<?xml version='1.0' encoding='utf-8'?>
<document id="20095910"><sentence text="Integrated opioid use disorder and HIV treatment: rationale, clinical guidelines for addiction treatment, and review of interactions of antiretroviral agents and opioid agonist therapies."><entity charOffset="11-17" id="DDI-PubMed.20095910.s1.e0" text="opioid" /></sentence><sentence text="Injection drug use (IDU) is an important vector of HIV infection in the United States" /><sentence text=" Many patients with HIV infection have comorbid substance use disorders" /><sentence text=" Integrated treatment for HIV and substance use disorders has been shown to improve HIV and other health outcomes, but significant barriers to integrated treatment exist" /><sentence text=" For individuals who are dependent on injection opioid drugs, agonist therapies of methadone or buprenorphine maintenance are available as part of a treatment program"><entity charOffset="83-92" id="DDI-PubMed.20095910.s5.e0" text="methadone" /><entity charOffset="96-109" id="DDI-PubMed.20095910.s5.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.20095910.s5.e0" e2="DDI-PubMed.20095910.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20095910.s5.e0" e2="DDI-PubMed.20095910.s5.e1" /></sentence><sentence text=" Patients who are infected with HIV and require antiretroviral therapy (ART) are at risk for drug-drug interaction between ART and methadone or buprenorphine"><entity charOffset="131-140" id="DDI-PubMed.20095910.s6.e0" text="methadone" /><entity charOffset="144-157" id="DDI-PubMed.20095910.s6.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.20095910.s6.e0" e2="DDI-PubMed.20095910.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20095910.s6.e0" e2="DDI-PubMed.20095910.s6.e1" /></sentence><sentence text=" We present a programmatic approach to the evaluation and treatment of opioid use disorders for HIV care providers, as well as a summary of the available knowledge of interactions of methadone and buprenorphine with ART, along with the level of evidence for each actual or potential interaction"><entity charOffset="183-192" id="DDI-PubMed.20095910.s7.e0" text="methadone" /><entity charOffset="197-210" id="DDI-PubMed.20095910.s7.e1" text="buprenorphine" /><pair ddi="false" e1="DDI-PubMed.20095910.s7.e0" e2="DDI-PubMed.20095910.s7.e0" /><pair ddi="false" e1="DDI-PubMed.20095910.s7.e0" e2="DDI-PubMed.20095910.s7.e1" /></sentence><sentence text=" Based on the available information of practice and the level of clinical significance of drug-drug interactions, we conclude that buprenorphine-based maintenance treatment for opioid dependent patients is the preferred maintenance therapy for integrated treatment systems"><entity charOffset="131-144" id="DDI-PubMed.20095910.s8.e0" text="buprenorphine" /></sentence><sentence text="" /></document>